z-logo
open-access-imgOpen Access
ER, PR, Cerb-B2, Ki-67, p53, Bcl-2, Cyclin-d1 Expressions in Invasive Breast Carcinomas and Comparison with the Clinical and Histopathological Parameters
Author(s) -
Özgür Çelik,
Serkan Çelik,
Yelda Dere,
Özcan Dere,
Önder Özcan
Publication year - 2018
Publication title -
journal of advanced research in medical and health science
Language(s) - English
Resource type - Journals
ISSN - 2208-2425
DOI - 10.53555/nnmhs.v4i9.606
Subject(s) - medicine , ki 67 , cyclin d1 , modified radical mastectomy , oncology , breast cancer , lymph node , immunohistochemistry , pathology , cancer research , cancer , mastectomy , cell cycle
Aim:The aim of this study was to evaluate ER(Estrogen-receptor), PR(Progesteron-receptor), cerb-B2, ki-67, p53, Bcl-2(B cell lymphoma-2), Cyclin-D1 expressions in invasive breast carcinomas and compare them with the clinical and histopathological parameters. Methods: We analyzed 70 female patients retrospectively who underwent Modified Radical Mastectomy with Axillary lymph node dissection and were diagnosed as Invasive ductal carcinoma of the breast-Not otherwise specified at Mu?la S?tk? Koçman University, Faculty of Medicine, Department of Pathology between 2012 and 2016. ER, PR, cerb-B2, ki-67, p53, Bcl-2, Cyclin-D1 expressions of these tumors were obtained by immunohistochemistry. Clinical parameters of the patients were obtained from the hospital automation system. Results: Bcl-2; was found to be more positive in patients with young age, small and low-grade, ER/ PR-positive tumors without distant organ metastasis. However Bcl-2 negativity was found to be higher in p53, cerb-B2 positive and fastly-growing (tumors with high ki-67 index) tumors. Cyclin-D1; was found to be more positive in small and low-grade, slowly-growing (tumors with low ki-67 index), cerb-B2 and p53 negative tumors without vascular invasion and axillary lymph node metastasis. Conclusion: These results were interpreted as; Bcl-2 and Cyclin-D1 positivity were in favor of better outcome and better prognosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here